ResearcherSahlgrenska University HospitalNo recent work listed

Kent Lundholm

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8727-6266; OpenAlex author ID A5035011694. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper

Papers 2

EGFR, but not COX-2, protein in resected pancreatic ductal adenocarcinoma is associated with poor survival. Last author DOI 10.3892/ol.2019.10224 ↗
Cost-utility estimations of palliative care in patients with pancreatic adenocarcinoma: a retrospective analysis. Last author DOI 10.1007/s00268-013-2003-z ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

David Ljungman · 2 shared papers, 2013–2019 · strength 0.17
- Paper EGFR, but not COX-2, protein in resected pancreatic ductal adenocarcinoma is associated with poor survival. DOI 10.3892/ol.2019.10224 ↗
- Paper Cost-utility estimations of palliative care in patients with pancreatic adenocarcinoma: a retrospective analysis. DOI 10.1007/s00268-013-2003-z ↗
Johan Bourghardt Fagman · 1 shared paper, 2019 · strength 0.11
- Paper EGFR, but not COX-2, protein in resected pancreatic ductal adenocarcinoma is associated with poor survival. DOI 10.3892/ol.2019.10224 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.